원저 : 유아혈관종에서 경구 프로프라놀롤의 효과 및 부작용에 대한 연구
분야
의약학 > 피부과학
저자
김선경 ( Sun Kyung Kim ) , 윤숙정 ( Sook Jung Yun ) , 김성진 ( Seong Jin Kim ) , 이승철 ( Semg Chul Lee ) , 원영호 ( Young Ho Won ) , 이지법 ( Jee Bum Lee )
발행기관
대한피부과학회
간행물정보
대한피부과학회지 2013년, 제51권 제9호, 698~704페이지(총7페이지)
파일형식
27728959.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    4,500원
    적립금
    135원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Background: Recently, propranolol has been found to be an effective treatment agent for infantile hemangiomas. Several studies have documented the effectiveness of propranolol in involution of infantile hemangiomas. The known side effects of propranolol include bronchospasm, hypoglycemia, bradycardia, hypotension, hyperkalemia, cool extremities,sleep disturbance, etc. However, the exact prevalence of adverse effects of this drug in Korean infants is unclear. Objective: The purpose of this study was to evaluate the efficacy and side effects of propranolol treatment in Korean patients with infantile hemangiomas. Methods: A total of 29 patients diagnosed with infantile hemangioma were treated with propranolol ranging from 1.5 to 2.5 mg/kg/day given either 2 or 3 times per day. Echocardiography and vital signs, blood glucose levels, and serum electrolytes were checked before and after each additional increased dose thereafter, and also during or at the end of the treatment period. All patients with IH took photographs and their parents were asked questions regarding their side effects at intervals of two months. Results: The mean age at treatment initiation was 3.9 months, and the average duration of treatment was 10.4months. Most of the patients (82.98%) showed good response with a clearance of 75% or more. Three (10.34%)patients had sleep disturbance and one (3.45%) had hyperkalemia. No patient was reported to have severe side effects such as symptomatic hypoglycemia, bradycardia, and hypotension. Conclusion: Based on these results, propranolol therapy is a very safe and highly effective modality for the treatment of Korean infants with infantile hemangiomas.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.